

Figure 22 shows results of proliferation assays using oligonucleotides (SEQ ID NOs:1, 101, 102) having 6-thioguanine substitution within the immunostimulatory dinucleotide.

Figure 23 shows results of spleen weight assays using oligonucleotides (SEQ ID NOs:1-5) having 5-hydroxycytosine or N4-ethylcytosine substitution within the immunostimulatory dinucleotide.

A' Figure 24 shows results of spleen weight assays using oligonucleotides (SEQ ID NOs:1-5) having 5-hydroxycytosine or N4-ethylcytosine substitution within the immunostimulatory dinucleotide.

Figure 25 shows results of proliferation assays using oligonucleotides (SEQ ID NOs:1, 111-112) having arabinofuranosylcytosine (aracytidine; Ara-C) substitution within the immunostimulatory dinucleotide.

Figure 26 shows results of spleen weight assays using oligonucleotides (SEQ ID NOs:1, 103-104) having 4-thiouracil substitution within the immunostimulatory dinucleotide.--

In the Sequence Listing

Please insert the substitute Sequence Listing information (copy enclosed) after the last page of the specification.

REMARKS

This amendment of the specification does not introduce any new subject matter. Applicants have provided herewith a substitute Sequence Listing which complies with the post July 1998 format. The formal drawings enclosed herewith have been amended to properly refer to the appropriate SEQ ID NOs.


No fees are believed to be due with the filing of this Preliminary Amendment. However,

U.S.S.N. 09/965,116
Kandimalla et al.
Page 5

the Commissioner is hereby authorized to debit Deposit Account No. 08-0219 for any required fee necessary to maintain the pendency of this application.

The Examiner is encouraged to telephone the undersigned to expedite the prosecution of this application.

Respectfully submitted,


Ann-Louise Kerner, Ph.D.
Registration No. 33,523
Agent for Applicant

Date: Dec 14, 2001

HALE AND DORR LLP
60 State Street
Boston, MA 02109
(617) 526-6000
(617) 526-5000 (Facsimile)